Thomas Voit, MD, PhD | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
Researchers

Thomas Voit, MD, PhD

Researcher
Director of Biomedical Research Centre
NIHR Great Ormond Street Hospital
UCL Institute of Child Health
R&D Office
30 Guilford Street
Bloomsbury
London, United Kingdom

Dr. Thomas Voit is the Director of the Biomedical Research Centre (BRC) at the Great Ormond Street Hospital (GOSH) and the UCL Institute of Child Health (ICH).  BRC was awarded its status by the National Institute for Health Research (NIHR) in 2007. It supports medical research for children and young people at GOSH and ICH. Their research aims to accelerate discoveries into the basis of childhood rare diseases and to develop new diagnostics, imaging techniques and treatments, including cellular and gene therapies.

Dr. Voit is a member of the Developmental Neurosciences Programme at the UCL Great Ormond Street Institute of Child Health. The primary focus of the Developmental Neuroscience Programme is to minimize the impact of disorders affecting the developing central and peripheral nervous system by studying the mechanisms of injury and repair, improving diagnosis and prognosis, evaluating therapeutic strategies and optimizing functional outcome.

Dr. Voit is a Faculty of Population Health Sciences at University College London. The institute delivers outstanding research and teaching for improved human health and well-being worldwide.

 

Representative Publications:

Ataluren treatment of patients with nonsense mutation dystrophinopathy

Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy

Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy

Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

rareRelated